NEW YORK (GenomeWeb) – Predicine and Flagship Biosciences said Thursday that they have agreed to enter a strategic venture, which will combine Predicine's GeneRADAR molecular insights platform with Flagship's artificial intelligence-enabled cTA digital pathology platform for pharmaceutical customers in the immuno-oncology space.
To read the full story....
...and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?
Login Now.
Don't have a 360Dx or GenomeWeb account?
Register for Free.